JP7473642B2 - Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 - Google Patents

Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 Download PDF

Info

Publication number
JP7473642B2
JP7473642B2 JP2022528124A JP2022528124A JP7473642B2 JP 7473642 B2 JP7473642 B2 JP 7473642B2 JP 2022528124 A JP2022528124 A JP 2022528124A JP 2022528124 A JP2022528124 A JP 2022528124A JP 7473642 B2 JP7473642 B2 JP 7473642B2
Authority
JP
Japan
Prior art keywords
compound
group
added
mmol
pharma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022528124A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023506691A (ja
JP2023506691A5 (https=
Inventor
ジャン，ヤン
ウー，ウェンタオ
ゲン，カイジュン
リィ，チウ
リィ，ジアン
チェン，シューホイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang Longcharm Bio Tech Pharma Co Ltd
Original Assignee
Zhejiang Longcharm Bio Tech Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Longcharm Bio Tech Pharma Co Ltd filed Critical Zhejiang Longcharm Bio Tech Pharma Co Ltd
Publication of JP2023506691A publication Critical patent/JP2023506691A/ja
Publication of JP2023506691A5 publication Critical patent/JP2023506691A5/ja
Application granted granted Critical
Publication of JP7473642B2 publication Critical patent/JP7473642B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022528124A 2019-11-13 2020-11-13 Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用 Active JP7473642B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN201911109773.2 2019-11-13
CN201911109773 2019-11-13
CN201911288492 2019-12-13
CN201911288492.8 2019-12-13
CN202010096582 2020-02-17
CN202010096582.3 2020-02-17
CN202010711270.9 2020-07-22
CN202010711270 2020-07-22
PCT/CN2020/128597 WO2021093839A1 (zh) 2019-11-13 2020-11-13 作为btk抑制剂的吡咯并嘧啶类化合物及其应用

Publications (3)

Publication Number Publication Date
JP2023506691A JP2023506691A (ja) 2023-02-20
JP2023506691A5 JP2023506691A5 (https=) 2023-02-28
JP7473642B2 true JP7473642B2 (ja) 2024-04-23

Family

ID=75912541

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022528124A Active JP7473642B2 (ja) 2019-11-13 2020-11-13 Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用

Country Status (6)

Country Link
US (1) US12378253B2 (https=)
EP (1) EP4059935A4 (https=)
JP (1) JP7473642B2 (https=)
KR (1) KR102793446B1 (https=)
CN (2) CN117551103A (https=)
WO (1) WO2021093839A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518790A (ja) * 2021-05-12 2024-05-02 ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4234558A4 (en) * 2020-12-07 2024-10-23 Zhejiang Longcharm Bio-Tech Pharma. Co., Ltd. PYRROLOPYRIDINE COMPOUND AND APPLICATION THEREOF
WO2022213932A1 (zh) * 2021-04-06 2022-10-13 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
CN114761410B (zh) * 2021-04-06 2023-08-25 广州必贝特医药股份有限公司 吡咯并嘧啶酮类化合物及其应用
KR20240157639A (ko) 2021-12-14 2024-11-01 크로스파이어 온콜로지 홀딩 비.브이. 거대고리 btk 억제제
CN115894500B (zh) * 2022-11-02 2024-05-28 中国药科大学 一种作为btk激酶抑制剂的化合物及其制备方法与用途
CN118702697A (zh) * 2023-03-18 2024-09-27 山东新时代药业有限公司 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN116375715B (zh) * 2023-04-06 2025-04-04 中国药科大学 一种作为非共价btk激酶抑制剂的化合物及其生物用途
WO2024245578A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a macrocyclic reversible btk inhibitor
WO2024245577A1 (en) 2023-06-02 2024-12-05 Netherlands Translational Research Center Holding B.V. Therapeutic combinations of an irreversible btk inhibitor and a reversible btk inhibitor
WO2024246287A1 (en) 2023-06-02 2024-12-05 Crossfire Oncology Holding B.V. Medical use of a macrocyclic reversible btk inhibitor
WO2024256568A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Salt and crystal forms of a macrocyclic btk inhibitor
WO2024256574A1 (en) 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538349A (ja) 2015-12-23 2018-12-27 アークル インコーポレイテッド テトラヒドロピラニルアミノ−ピロロピリミジノンおよびその使用の方法
JP2019530650A (ja) 2016-08-24 2019-10-24 アークル インコーポレイテッド アミノ−ピロロピリミジノン化合物およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
EP3170825B1 (en) * 2012-08-06 2019-04-10 ACEA Biosciences Inc. Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
EP3042903B1 (en) * 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018538349A (ja) 2015-12-23 2018-12-27 アークル インコーポレイテッド テトラヒドロピラニルアミノ−ピロロピリミジノンおよびその使用の方法
JP2019530650A (ja) 2016-08-24 2019-10-24 アークル インコーポレイテッド アミノ−ピロロピリミジノン化合物およびその使用方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024518790A (ja) * 2021-05-12 2024-05-02 ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法
JP7645573B2 (ja) 2021-05-12 2025-03-14 ジャージアン・ロングチャーム・バイオ－テック・ファーマ・カンパニー・リミテッド ピロロピリミジン類化合物の結晶形およびその調製方法

Also Published As

Publication number Publication date
EP4059935A1 (en) 2022-09-21
KR102793446B1 (ko) 2025-04-09
CN114728974A (zh) 2022-07-08
KR20220097455A (ko) 2022-07-07
EP4059935A4 (en) 2024-02-28
CN117551103A (zh) 2024-02-13
JP2023506691A (ja) 2023-02-20
US20230357248A1 (en) 2023-11-09
CN114728974B (zh) 2023-09-19
WO2021093839A1 (zh) 2021-05-20
US12378253B2 (en) 2025-08-05

Similar Documents

Publication Publication Date Title
JP7473642B2 (ja) Ｂｔｋ阻害剤としてのピロロピリミジン系化合物およびその使用
AU2017284702B2 (en) Pyrrolopyrimidine crystal for preparing JAK inhibitor
RU2118317C1 (ru) (-)-[[4-(1,4,5,6-тетрагидро-4-метил-6-оксо-3-пиридазинил)фенил]гидразоно]пропандинитрил и его фармацевтически приемлемые соли, фармацевтическая композиция на его основе, способ получения промежуточного соединения и способ получения целевого соединения
JP7710223B2 (ja) 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用
AU2020295703A1 (en) EGFR inhibitor for the treatment of cancer
JP2023502407A (ja) 選択性の高いｒｏｓ１阻害剤としての化合物、及びその使用
EP3992189A1 (en) Quinazoline and cinnoline derivatives as dna-pk inhibitor
JP2011515370A (ja) ４−アミノ−５−フルオロ−３−［５−（４−メチルピペラジン−１−イル）−１ｈ−ベンズイミダゾール−２−イル］キノリン−２（１ｈ）−オン乳酸塩の結晶形態及び２つの溶媒和物形態
CN110143950A (zh) 药物化合物
BR112021014456A2 (pt) Inibidores de di-hidro-orotato desidrogenase
JP2022549866A (ja) Ｃｒａｃ阻害剤としての２ｈ－ベンゾピラン誘導体
AU2020405326A1 (en) EGFR inhibitors
WO2021099837A1 (en) Adenosine receptor antagonist compounds
WO2019134573A1 (zh) 一种氘代二苯氨基嘧啶类化合物的制备方法及其晶型
AU2024289347A1 (en) Nmt inhibitor, and preparation method therefor and use thereof
WO2011082271A2 (en) Substituted triazolo-pyrimidine compounds
JP2022507461A (ja) ブルトン型チロシンキナーゼの阻害剤
AU2011337033A1 (en) Oxazolo [5, 4 -b] pyridin- 5 -yl compounds and their use for the treatment of cancer
HK40080199A (en) Pyrrolopyrimidine compound as btk inhibitor and use thereof
JP2019522651A (ja) タンパク質キナーゼ阻害剤としての置換されているピロロ［２，３−ｄ］ピリダジン−４−オン及びピラゾロ［３，４−ｄ］ピリダジン−４−オン
JP2023543006A (ja) １Ｈ－ピロロ［２，３－ｃ］ピリジン系化合物及びその使用
CN115894376B (zh) 一种芳香族酰胺类化合物、药物组合物及其用途
WO2021240423A1 (en) Dihydroorotate dehydrogenase inhibitors
JP2021531331A (ja) チアジアゾール誘導体及びｇｌｓ１阻害剤としてのその使用
CN118139865A (zh) 吡咯并吡唑螺环化合物

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20221006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221006

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231031

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240125

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240411

R150 Certificate of patent or registration of utility model

Ref document number: 7473642

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150